The new technology, Revivent, is designed for use in less invasive ventricular enhancement (LIVE) procedures to improve the function of the left ventricle (LV) without an incision in the heart wall and to reduce LV volume by excluding scarred myocardial tissue from the chamber.

In addition, the use of the technology in LIVE procedures reduces the harmful effects of high-tensile forces and increasing pumping efficiency in the ventricle and restores it into conical geometry, resulting in enhanced performance of the remaining myocardium.

BioVentrix president and chief executive officer Ken Miller said Revivent system used during LIVE procedures will help cardiac surgery teams ensure optimal clinical outcomes and improve the quality of life for heart failure patients with very minimal risk in comparison to currently available conventional LV reconstruction surgical procedures.

"Scientific literature suggests that existing treatment options such as medication or pacemaker therapy, are not effective in over half of those treated, which exemplifies the need for minimally invasive cardiac surgery to treat the growing population of patients who suffer from heart failure," Miller added.